Comprehensive Review on Hair Loss and Restorative Techniques: Advances in Diagnostic, Artistry, and Surgical Innovation.

Luis A Mendoza, Genaro G Ocampo, Yozahandy A Abarca-Pineda, Mubashir Ahmad Khan, Yasmin Ahmadi et al.

Review Cureus 2025 2 citations

<\/script>\n

`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'pmid\u003D40416167'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Study Design

Study Type: Review

Intervention: Comprehensive Review on Hair Loss and Restorative Techniques: Advances in Diagnostic, Artistry, and Surgical Innovation. None
Comparator: Placebo
Effect Direction: Positive
Risk of Bias: Unclear

Abstract

Hair loss, or alopecia, is a complex disorder that impacts individuals worldwide, frequently resulting in significant psychological and social consequences. This review analyzes the multifactorial etiology, recent diagnostic innovations, and emerging treatment alternatives for hair loss management. Alopecia is classified into the cicatricial (scarring) and non-cicatricial (non-scarring) forms, each having a unique underlying pathogenesis, ranging from autoimmune dysregulation, androgenetic mechanisms, and environmental factors. Recent advancements in diagnostics, such as artificial intelligence (AI)-enhanced imaging and biomarker analysis, have improved precision and individualization of treatment. Novel therapies, such as low-dose oral minoxidil (LDOM), topical 5-alpha reductase inhibitors, and Janus kinase inhibitors (JAKi), offer a range of promising options for hair loss management. Non-invasive therapies, such as low-level laser therapy (LLLT) and platelet-rich plasma (PRP) injections, have demonstrated synergistic benefits with existing treatments. Surgical advancements, especially AI-assisted robotic follicular unit extraction (FUE), enhance precision and outcomes. Emerging trends in regenerative medicine, especially stem-cell-based therapies and AI integration, are influencing the future of customized hair restoration. This review serves as a comprehensive guide, highlighting the use of innovative technologies and therapies in enhancing the accuracy and customization of hair loss treatment.

Full Text

PDF

Loading PDF...

Tables

Table 1

Subtype	Mechanism	Clinical Features	Examples
Primary CA	- Direct inflammatory damage to the hair follicle - Inflammatory infiltrates (lymphocytic, neutrophilic, or mixed)	- Follicular destruction - Loss of follicular openings - Scalp burning, itching, tenderness	Frontal fibrosing alopecia, central centrifugal cicatricial alopecia, lichen planopilaris
Secondary CA	- Chronic inflammation secondary to external factors (e.g., trauma, infection, toxins)	- Follicular atrophy - Permanent scarring - Associated with external insults	Traction alopecia, chemotherapy-induced alopecia

Table 2

Type	Significant features	Hair Pull Test	Trichoscopy	Treatment and comments
ACNE KELOIDALIS NUCHAE (AKN)	Papules, pustules, and keloid masses occurring in the occiput and nuchal region.	Negative	Early stages: Erythematous papules and pustules, perifollicular scales, and hemorrhagic and honey-colored crusts. Advanced stages: Perifollicular white halos, black dots, broken hair shafts, dilated follicular ostia, and keratin or hair tufts. Keloid-like lesions: Milky-red areas with no follicular ostia	Overall, the treatment of AKN is difficult and unsatisfactory. Patient education, avoiding close shaving and frequent haircuts, topical antimicrobials, mild keratolytic agents, or topical steroids with or without a retinoid.
CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA (CCCA)	Occurs centrally and spreads peripherally and symmetrically.	Positive	Asterisk-like brown blotches, broken hairs, and dark peripilar halos.	Topical minoxidil, topical fluocinonide and ketoconazole shampoo. Intralesional triamcinolone injections (alone, with topicals, or with topicals and oral medication).
DISCOID LUPUS ERYTHEMATOSUS	Erythematous alopecic patch with follicular hyperkeratosis and areas of hyper- and hypopigmentation occurring on the scalp. Patients can also have lesions located on the face and ears.	Positive if concurrent with other kinds of alopecia (TE, AE, AA, etc.).	Thick arborizing vessels, follicular keratotic plugs, follicular red dots, peripilar scale, and peripilar erythema. Blue-gray speckled dots and blue-white veil are two features observed in patients with Fitzpatrick skin types IV-VI.	First-line therapy includes: Topical clobetasol under occlusion 4-5 days/week + Topical minoxidil.
DISSECTING CELLULITIS	Alopecia occurring most commonly on the vertex and occiput that results from multiple firm to fluctuant inflammatory nodules, abscesses, and plaques on the scalp, with an overlying patch of alopecia.	Positive, revealing broken hairs at different lengths.	Yellow dots: A 3D structure over dystrophic hair shafts is a characteristic finding. Early stage of dissecting cellulitis. Yellow structureless areas: These areas are "lakes of pus" that are often found around hair follicles. Black dots: Often found in active lesions. Pinpoint-like vessels: These vessels have a whitish halo and can be observed. Polytrichia: This is the emergence of five or more shafts per follicular unit. Skin clefts with emergent hairs: These are skin folds that contain shafts. White dots and amorphous white areas: These represent empty follicular units replaced by fibrosis. Blue-gray dots: These dots have a histopathological correspondence to pigmentary incontinence.	Comprises a variety of medications and other therapies: antibiotics (erythromycin), steroids (prednisolone), retinoids (oral or topical), and surgical excision, split-thickness skin grafting, or laser hair removal are considered for unresponsive cases.
FRONTAL FIBROSING ALOPECIA	Alopecic band occurring along the fronto-temporal region and often includes eyebrows. Can present with a pseudo-fringe sign, which is when some hair is retained along the original hairline.	Negative.	Loss of follicular openings (on the frontotemporal hairline), perifollicular erythema, follicular hyperkeratosis, absence of vellus hairs and solitary terminal hairs (both helpful clinical clues for diagnosis). Other findings are: yellow dots, perifollicular blue-gray dots, etc.	Has no cure. Can help slow progression: antibiotics, intralesional corticosteroids or as cream, finasteride or dutasteride, hydroxychloroquine, minoxidil.
LICHEN PLANOPILARIS (LPP)	Can occur in patchy, diffuse, or patterned form. Patchy: Alopecia occurs in small patches and merges to form larger alopecic patches. Diffuse: Alopecia generally starts at the crown. Patterned: Blend of androgenic alopecia and diffuse LPP.	Positive, used to measure the activity of lichen planopilaris (lichen planopilaris activity index, LPPAI).	Inflammation is mainly folliculocentric, erythema and scaling will have a perifollicular pattern of distribution. Scales form tubular structures around shafts, called casts. Small tufts containing 2-4 hair shafts surrounded by scaling are very suggestive of the diagnosis. Pili torti are commonly observed, but is also seen in all forms of primary cicatricial alopecias.	Comprises a variety of therapies: topical treatments (cortisone lotions, retinoids, calcineurin inhibitors), oral treatments (hydroxychloroquine, tetracyclines, immunosuppressants), intralesional corticosteroids, low-level laser therapy, etc, antimalarial drugs.

Table 3

Subtype	Mechanism	Clinical Features	Examples
Patchy	- Immune-mediated or localized disruption of follicular function	- Localized hair loss - Preserved follicular openings - Potential for regrowth	Tinea capitis, trichotillomania
Diffuse	- Systemic or environmental factors affecting the hair growth cycle	- Generalized thinning or shedding - No scarring - Potentially reversible	Telogen effluvium (TE), anagen effluvium

Table 4

Treatment	Mechanism	Indications	Adverse effects
Topical
Minoxidil	Shortens telogen phase, prolongs anagen phase, enhances blood flow via VEGF upregulation	AGA, TE, AA, FFA, TA, Chemotherapy-induced alopecia, Loose anagen hair syndrome, Monilethrix	Pruritus, irritation, hypertrichosis, initial shedding
Finasteride	Inhibits 5-alpha reductase, blocks formation of DHT	AGA	Irritation, erythema, contact dermatitis
Clascoterone	Androgen receptor inhibitor	AGA (experimental)	Weight gain, breast tenderness, decreased libido
Latanoprost and bimatoprost	Prostaglandin analogs; prolong the anagen (growth) phase	AGA (experimental)	Irritation, hypertrichosis
Systemic
Low-dose Oral Minoxidil	Shortens telogen phase, prolongs anagen phase, enhances blood flow via VEGF upregulation	AGA, TE, AA, FFA, TA, Chemotherapy-induced alopecia, Loose anagen hair syndrome, Monilethrix	Hypertrichosis, hypotension, lower limb edema, heart rate changes
Finasteride	Type II 5-alpha-reductase inhibitor; blocks the formation of DHT	AGA	Reduced libido, erectile dysfunction, depression, gynecomastia
Dutasteride	Type I and II 5-alpha-reductase inhibitors; blocks the formation of DHT	AGA	Reduced libido, erectile dysfunction, depression, gynecomastia
Spironolactone	Antiandrogen; decreases testosterone	AGA (FPHL)	Postural hypotension, electrolyte imbalances, breast tenderness, menstrual irregularities
Flutamide and bicalutamide	Antiandrogen; blocks testosterone	AGA (FPHL)	Elevated liver enzymes, headache, breast tenderness
Cyproterone acetate	Antiandrogen; blocks gonadotropin-releasing hormone and androgen receptors	AGA (FPHL)	Weight gain, breast tenderness, reduced libido
JAK inhibitors	Inhibit the JAK-STAT pathway, reduce inflammatory cytokine signaling	AA	Increased infection risk, thrombosis, neutropenia
Biologics	Target specific cytokine pathways like IL-4/IL-13 or IL-12/IL-23	AA	Injection site reactions, conjunctivitis, respiratory infections
Injectables
Dutasteride	Type I and II 5-alpha-reductase inhibitor; blocks the formation of DHT in the hair follicle	AGA	Scalp pain